Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.

Cancer Medicine
Deborah L Toppmeyer, Michael F Press

Abstract

Breast cancer is the most common cancer in women, and approximately 71% of carcinomas are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-not-amplified (HER2-negative). Pathogenesis of breast cancer is associated with dysregulation of several signaling pathways, including the phosphatidylinositol-3-kinase (PI3K) pathway. PIK3CA, the gene encoding PI3K catalytic subunit p110α, is mutated in 20%-40% of breast cancer patients. Several PI3K inhibitors have been developed and one, alpelisib, was recently approved for use in PIK3CA-mutated, HR+, HER2-negative advanced breast cancer. There are numerous types of assays and methods used in clinical studies to determine PIK3CA status in cancers. Additionally, there are several factors to consider for PIK3CA testing in clinical practice, including choice of assay, source of sample, and test timing. In this review, we discuss the use of PIK3CA as a biomarker to guide treatment decisions in patients with HR+, HER2-negative advanced breast cancer, as well as practical considerations and recommendations for testing.

References

Dec 6, 2002·The American Journal of Pathology·Mythily SrinivasanScott Jewell
Dec 13, 2005·Nature Reviews. Drug Discovery·Bryan T HennessyGordon B Mills
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Aug 1, 2009·Nature Reviews. Drug Discovery·Pixu LiuJean J Zhao
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Mar 15, 2013·The New England Journal of Medicine·Sarah-Jane DawsonNitzan Rosenfeld
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Nov 5, 2013·Nature Genetics·Dan R RobinsonArul M Chinnaiyan
Nov 5, 2013·Nature Genetics·Weiyi ToySarat Chandarlapaty
Nov 26, 2013·Nature Genetics·Steffi Oesterreich, Nancy E Davidson
Nov 30, 2013·Breast Cancer Research : BCR·Suzanne A EcclesAlastair M Thompson
Dec 24, 2014·Nature Reviews. Cancer·Lauren M ThorpeJean J Zhao
Feb 5, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Howard M SternMichael F Press
Jun 2, 2015·Breast Cancer : Targets and Therapy·Toru Mukohara
Nov 22, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zachary ZumstegJose Baselga
Mar 31, 2016·Oncotarget·François BertucciMax Chaffanet
Apr 23, 2016·Clinical Breast Cancer·Hyo Sook Han, Anthony M Magliocco
Oct 19, 2016·Applied Immunohistochemistry & Molecular Morphology : AIMM·Maria G KubaGiovanna A Giannico
May 20, 2017·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Angela B MariottoMusa Mayer
Oct 17, 2017·The Journal of Spinal Cord Medicine
Jan 19, 2018·Journal of Cellular Biochemistry·Navid SobhaniDaniele Generali
Feb 23, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitrios ZardavasSherene Loi
Mar 6, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason D MerkerNicholas C Turner
May 19, 2018·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Michael J DuffyJohn Crown
May 31, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffMitchell Dowsett
Sep 12, 2018·Cancer Cell·Pedram RazaviJosé Baselga
Nov 6, 2018·Endocrine-related Cancer·Neil PortmanC Elizabeth Caldon
Jan 24, 2019·Clinical Genetics·Sahar AlimirzaieMohammad R Akbari
May 16, 2019·The New England Journal of Medicine·Fabrice AndréUNKNOWN SOLAR-1 Study Group
Feb 12, 2020·Archives of Pathology & Laboratory Medicine·Timothy Kwang Yong Tay, Puay Hoon Tan
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F AndréD Juric

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
PCR
biopsies
genotyping

Clinical Trials Mentioned

NCT02437318

Software Mentioned

SOLAR

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Autophagosome

An autophagosome is the formation of double-membrane vesicles that involve numerous proteins and cytoplasmic components. These double-membrane vesicles are then terminated at the lysosome where they are degraded. Discover the latest research on autophagosomes here.

Autophagosome

An autophagosome is the formation of double-membrane vesicles that involve numerous proteins and cytoplasmic components. These double-membrane vesicles are then terminated at the lysosome where they are degraded. Discover the latest research on autophagosomes here.